All > Obsessive Compulsive Disorder > Tdcs

Behavioural Intervention

Active tDCS for Obsessive-Compulsive Disorder

Massachusetts General Hospital, Boston, MA

Active tDCS +1 moreN/ARecruitingLed by Joan Camprodon, MD, MPH, PhDResearch Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Primary OCD that causes at least moderate distress and/or impairment (Y-BOCS total score ≥ 16)

Must not have

Be younger than 18 years old

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upextinction recall phase (day 2)

Awards & highlights

Study Summary

This trial will investigate whether tDCS can help people with OCD to better control their fear.

Eligible Conditions

Obsessive-Compulsive Disorder

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

You have OCD that causes moderate distress or affects your ability to function normally (Y-BOCS total score ≥ 16).

Select...

You have OCD that causes significant distress and interference in your daily life.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ extinction recall phase (day 2)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~extinction recall phase (day 2)

This trial's timeline: 3 weeks for screening, Varies for treatment, and extinction recall phase (day 2) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Difference in frontomedial theta power (EEG) to the conditioned stimulus (CS+) versus the unconditioned stimulus (CS-) between tDCS conditions during extinction recall

Difference in skin conductance response (SCR) to the conditioned stimulus (CS+) versus the unconditioned stimulus (CS-) between tDCS conditions during extinction recall

Side effects data

From 2012 Phase 3 trial • 60 Patients • NCT01649232

10%

headache

10%

headedness / dizziness

fatigue or nausea

100%

80%

60%

40%

20%

Study treatment Arm

Active tDCS

Controls

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Active tDCS administered during extinction phaseExperimental Treatment1 Intervention

The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.

Group II: Active tDCS administered before extinction phaseExperimental Treatment1 Intervention

The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.

Group III: Active tDCS administered after extinction phaseExperimental Treatment1 Intervention

The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.

Group IV: Sham tDCSPlacebo Group1 Intervention

Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Active tDCS

2012

Completed Phase 3

~860

0 / 2Eligibility criteria met

Find a site

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,833 Previous Clinical Trials

13,567,211 Total Patients Enrolled

26 Trials studying Obsessive-Compulsive Disorder

1,575 Patients Enrolled for Obsessive-Compulsive Disorder

Foundation for OCD ResearchUNKNOWN

1 Previous Clinical Trials

360 Total Patients Enrolled

1 Trials studying Obsessive-Compulsive Disorder

360 Patients Enrolled for Obsessive-Compulsive Disorder

Joan Camprodon, MD, MPH, PhDPrincipal Investigator

Massachusetts General Hospital

Media Library

tDCS (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05521074 — N/A

Obsessive-Compulsive Disorder Research Study Groups: Active tDCS administered after extinction phase, Sham tDCS, Active tDCS administered during extinction phase, Active tDCS administered before extinction phase

Obsessive-Compulsive Disorder Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT05521074 — N/A

tDCS (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05521074 — N/A

Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT05521074 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are currently taking part in this clinical trial?

"Affirmative. Records from clinicaltrials.gov indicate that this study began recruiting on September 15th 2022, and is still actively seeking patients as of October 3rd 2022. The investigation requires 120 people to be enlisted at 1 medical centre."

Answered by AI

Is there a possibility of me participating in this trial?

"This clinical trial is searching for 120 participants between the ages of 18 and 60 who suffer from obsessive-compulsive disorder (OCD). To be eligible, individuals must have a Y-BOCS total score that is at least 16, demonstrate competency with computers and English language skills, consent to take part in the study, and agree to comply with all protocol requirements."

Answered by AI

Is this investigation actively seeking new participants?

"Affirmative. Clinicaltrials.gov has information noting that this clinical trial, which was first advertised on September 15th 2022, is in the process of recruiting participants. Approximately 120 individuals are needed for research from 1 different medical institution."

Answered by AI

Is the age limit for this research study inclusive of those under 40 years old?

"The upper and lower age limits for this study are 18 to 60, with 23 studies open for minors aged under 18 and 67 trials available specifically to those over 65."

Answered by AI